Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences – CNBC

Share this Story

In its complaint last month, the FTC raised concerns that Illumina wanted the deal in order to prevent Pacific Biosciences from developing into a competitor in the market for next-generation DNA sequencing.

Author: Reuters

READ MORE